Tumor Necrosis Factor Inhibitor Drugs Market

Tumor Necrosis Factor Inhibitor Drugs Market by Product (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and Biosimilars), Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, and Others), Sales Channel (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-795
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 135
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global tumor necrosis factor inhibitor drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing incidence of autoimmune diseases, new product launches and growing consumer awareness.

Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and juvenile idiopathic arthritis (JIA) are all autoimmune diseases that cause severe pain. Many people with rheumatologic autoimmune disease go months or years without knowing what is causing their pain, and standard pain relievers like nonsteroidal anti-inflammatory drugs (NSAIDs) do not work as well as they should. When a patient does not react to usual treatment, an autoimmune disease process should be suggested as a promising cause. Tumor necrosis factor (TNF) inhibitors are anti-inflammatory medications. Rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn's disease are all disorders that are treated with them. TNF blockers, biologic therapies, and anti-TNF drugs are all terms used to describe these tumor necrosis factor. TNF inhibitors are relatively new additions to the armamentarium of drugs used to treat autoimmune diseases. In 1998, the FDA approved Remicade (infliximab) and Enbrel (etanercept) for the first time. Humira (adalimumab) received FDA approval in 2002, followed by Cimzia (certolizumab pegol) in 2008, and Simponi (golimumab) in 2009. Simponi Aria, a golimumab IV infusion formulation, was authorized in 2013.

Tumor necrosis factor inhibitors are laboratory produced antibodies from human or animal tissue. Antibodies are produced by the body to fight infections. When they are injected into the bloodstream, they trigger an immune system reaction that prevents inflammation. Tumor necrosis factor is a substance produced by the immune system (TNF). TNF levels are usually maintained by the body. However, something goes wrong if the patient has an autoimmune condition like Rheumatoid arthritics. The body produces too much TNF, which causes inflammation. Your body can be harmed by excess inflammation. You may get pain, swelling, or become sick as a result of this. TNF actions are suppressed by these medicines. After their initial dose, most people feel much better in 2 to 4 weeks. Your symptoms could improve even more after 3 to 6 months. Some TNF inhibitors are administered as shots under the skin, such as Cimzia, Humira, Enbrel, Erelzi, and Simponi. Infusions of Remicade, Inflectra, and Simponi Aria, a Simponi variant, are administered at a clinic or doctor's office. TNF inhibitors may also be prescribed in conjunction with other medications such as methotrexate, prednisone, hydroxychloroquine (Plaquenil), leflunomide (Arava), or sulfasalazine (Azulfidine). Tumor necrosis factor inhibitor are proved to be beneficial in chronic pain management for certain autoimmune conditions.

Global Tumor Necrosis Factor Inhibitor Drugs Market Summary

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing incidence of autoimmune diseases around the world is projected to drive the market growth during the forecast period.
  • Favorable reimbursement policies by governments are anticipated to fuel the market growth during the forecast period.
  • Increasing geriatric population around the world is anticipated to spur the market the growth during the forecast period.
  • Technological advancements and increased expenditure on healthcare are key factors driving the market growth during the forecast period.
  • Growing consumer demand for cost effective treatment with improved safety and efficacy profiles are expected to drive the market growth during the forecast period.
  • Rising consumer awareness worldwide regarding the benefits of tumor necrosis factor inhibitor drugs are anticipated to propel the market growth in the coming years.
  • High cost of the TNF inhibitors drugs and stringent regulatory framework possess as key challenges that can hamper the market growth during the forecast period.
  • Increased emphasis on R&D for novel drug development is projected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global tumor necrosis factor inhibitor drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Tumor Necrosis Factor Inhibitor Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Product (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and Biosimilars), Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, and Others), Sales Channel (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A.; Novartis International AG; Pfizer, Inc.; Merck & co., Inc.

 

Market Segment Insights

Humira segment is expected to account for a key share of the market
Based on product, the tumor necrosis factor inhibitor drugs market is segmented into humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. The humira segment is expected to account for a key share of the market during the forecast period owing to its cost effectiveness and efficacy. Although Humira's patent in Europe ended in 2018, the product's patent exclusivity in the United States is retained until 2023. The loss of patent exclusivity is expected to result in lower sales, although Humira is expected to remain at the top of the TNF inhibitor market. Biosimilars are posing a severe challenge to biologics, owing to their low cost and consistent results in head-to-head clinical trials. Humira, Enbrel, and Remicade all have biosimilar versions in the market.

Global Tumor Necrosis Factor Inhibitor Drugs Market By Product

Rheumatoid arthritis segment is expected to constitute a key share of the market
Based on application, the tumor necrosis factor inhibitor drugs market is segmented into rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others. The rheumatoid arthritis segment is expected to constitute a key share of the market during the forecast period owing to increased product penetration and high treatment rate.

On the other hand, the psoriasis and psoriatic arthritis segment is anticipated to expand at a rapid pace during the forecast period owing to increasing disease prevalence, consumer awareness, and favorable reimbursement policies. Furthermore, favorable initiatives by public and private institutes for increasing consumer awareness is expected to drive the segment growth further.

Hospital pharmacies segment is expected to hold a key share of the market
Based on sales channel, the tumor necrosis factor inhibitor drugs market is segmented into hospital pharmacies, specialty pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period coming due to rising patient turnover in hospitals. Rather than retail pharmacies, specialty pharmacies sell the majority of biologics and biosimilars. Specialty pharmacies have a number of advantages, including the ability to create disease-specific care plans that are tailored to each patient's needs, thereby addressing financial concerns while also improving outcomes.

Global Tumor Necrosis Factor Inhibitor Drugs Market By Sales Channel

North America is anticipated to dominate the market
On the basis of regions, the tumor necrosis factor inhibitor drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to existence of key players, effective government initiatives, favorable reimbursement policies, and a huge patient pool.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increased adoption of biosimilars in emerging economies such as China, India, and South Korea. Furthermore, regional demand is likely to be driven by overall economic development, improvements in healthcare facilities, more disposable income, and increased consumer awareness.

Global Tumor Necrosis Factor Inhibitor Drugs Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tumor Necrosis Factor Inhibitor Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Tumor Necrosis Factor Inhibitor Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Tumor Necrosis Factor Inhibitor Drugs Market - Supply Chain
  4.5. Global Tumor Necrosis Factor Inhibitor Drugs Market Forecast
     4.5.1. Tumor Necrosis Factor Inhibitor Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Tumor Necrosis Factor Inhibitor Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Tumor Necrosis Factor Inhibitor Drugs Market Absolute $ Opportunity
5. Global Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     5.3.1. Humira
     5.3.2. Enbrel
     5.3.3. Remicade
     5.3.4. Simponi/Simponi Aria
     5.3.5. Cimzia
     5.3.6. Biosimilars
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     6.3.1. Rheumatoid Arthritis
     6.3.2. Psoriasis
     6.3.3. Psoriatic Arthritis
     6.3.4. Crohn’s Disease
     6.3.5. Ulcerative Colitis
     6.3.6. Ankylosing Spondylitis
     6.3.7. Juvenile Idiopathic Arthritis
     6.3.8. Hidradenitis Suppur
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
8. North America Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     8.4.1. Humira
     8.4.2. Enbrel
     8.4.3. Remicade
     8.4.4. Simponi/Simponi Aria
     8.4.5. Cimzia
     8.4.6. Biosimilars
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     8.7.1. Rheumatoid Arthritis
     8.7.2. Psoriasis
     8.7.3. Psoriatic Arthritis
     8.7.4. Crohn’s Disease
     8.7.5. Ulcerative Colitis
     8.7.6. Ankylosing Spondylitis
     8.7.7. Juvenile Idiopathic Arthritis
     8.7.8. Hidradenitis Suppur
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
9. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     9.4.1. Humira
     9.4.2. Enbrel
     9.4.3. Remicade
     9.4.4. Simponi/Simponi Aria
     9.4.5. Cimzia
     9.4.6. Biosimilars
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     9.7.1. Rheumatoid Arthritis
     9.7.2. Psoriasis
     9.7.3. Psoriatic Arthritis
     9.7.4. Crohn’s Disease
     9.7.5. Ulcerative Colitis
     9.7.6. Ankylosing Spondylitis
     9.7.7. Juvenile Idiopathic Arthritis
     9.7.8. Hidradenitis Suppur
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
10. Europe Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     10.4.1. Humira
     10.4.2. Enbrel
     10.4.3. Remicade
     10.4.4. Simponi/Simponi Aria
     10.4.5. Cimzia
     10.4.6. Biosimilars
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     10.7.1. Rheumatoid Arthritis
     10.7.2. Psoriasis
     10.7.3. Psoriatic Arthritis
     10.7.4. Crohn’s Disease
     10.7.5. Ulcerative Colitis
     10.7.6. Ankylosing Spondylitis
     10.7.7. Juvenile Idiopathic Arthritis
     10.7.8. Hidradenitis Suppur
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     11.4.1. Humira
     11.4.2. Enbrel
     11.4.3. Remicade
     11.4.4. Simponi/Simponi Aria
     11.4.5. Cimzia
     11.4.6. Biosimilars
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     11.7.1. Rheumatoid Arthritis
     11.7.2. Psoriasis
     11.7.3. Psoriatic Arthritis
     11.7.4. Crohn’s Disease
     11.7.5. Ulcerative Colitis
     11.7.6. Ankylosing Spondylitis
     11.7.7. Juvenile Idiopathic Arthritis
     11.7.8. Hidradenitis Suppur
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Types
     12.4.1. Humira
     12.4.2. Enbrel
     12.4.3. Remicade
     12.4.4. Simponi/Simponi Aria
     12.4.5. Cimzia
     12.4.6. Biosimilars
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market Size and Volume Forecast by Applications
     12.7.1. Rheumatoid Arthritis
     12.7.2. Psoriasis
     12.7.3. Psoriatic Arthritis
     12.7.4. Crohn’s Disease
     12.7.5. Ulcerative Colitis
     12.7.6. Ankylosing Spondylitis
     12.7.7. Juvenile Idiopathic Arthritis
     12.7.8. Hidradenitis Suppur
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Tumor Necrosis Factor Inhibitor Drugs Market: Market Share Analysis
  13.2. Tumor Necrosis Factor Inhibitor Drugs Distributors and Customers
  13.3. Tumor Necrosis Factor Inhibitor Drugs Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. AbbVie Inc.
     13.4.2. Amgen Inc.
     13.4.3. Johnson & Johnson Services, Inc.
     13.4.4. UCB S.A.
     13.4.5. Novartis International AG
     13.4.6. Pfizer, Inc.
     13.4.7. Merck & co., Inc.
Segments Covered in the Report
The global tumor necrosis factor inhibitor drugs market has been segmented on the basis of

Product
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars
Application
  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others
Sales Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • UCB S.A.
  • Novartis International AG
  • Pfizer, Inc.
  • Merck & co., Inc.

Key players competing in the tumor necrosis factor inhibitor drugs market include/are AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A.; Novartis International AG; Pfizer, Inc.; and Merck & co., Inc.

New products have a major clinical advantage over existing products in terms of safety and efficacy, or the end result, as regulatory procedures becoming stricter and competition intensifying. As a result, several head-to-head studies have been conducted comparing significant commercial medications like Humira and Remicade and novel treatments or late-stage pipeline prospects. The superiority of performance is determined in these trials by a comparison of numerous metrics. Therefore, some of key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares.

For example, in May 2019, the US Food and Drug Administration approved the use of Eticovo (SB4), a biosimilar developed by Samsung Bioepis Co., Ltd. in South Korea. It is Enbreland's second biosimilar, and it's used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis, among other conditions.

Global Tumor Necrosis Factor Inhibitor Drugs Market Key Players

Buy Report